Earl Douglas's most recent trade in Allogene Therapeutics Inc was a trade of 6,404 Common Stock done at an average price of $1.7 . Disclosure was reported to the exchange on Feb. 3, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Allogene Therapeutics Inc | Earl Douglas | SVP, General Counsel | Sale of securities on an exchange or to another person at price $ 1.71 per share. | 03 Feb 2025 | 6,404 | 587,848 (0%) | 0% | 1.7 | 10,951 | Common Stock |
Allogene Therapeutics Inc | Earl Douglas | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 512,370 | 512,370 | - | - | Stock Option (Right to buy) | |
Allogene Therapeutics Inc | Earl Douglas | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 144,928 | 594,252 (0%) | 0% | 0 | Common Stock | |
Allogene Therapeutics Inc | Earl Douglas | SVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.78 per share. | 21 Aug 2024 | 28,310 | 449,324 (0%) | 0% | 2.8 | 78,843 | Common Stock |
Allogene Therapeutics Inc | Earl Douglas | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 147,778 | 147,778 | - | - | Stock Option (Right to buy) | |
Allogene Therapeutics Inc | Earl Douglas | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 41,800 | 477,634 (0%) | 0% | 0 | Common Stock |